Drug Trial Radar · NCT05418673
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
Last checked: Nov 19, 2026Latest source record: Jun 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
7
Actual
Start
Aug 26, 2022
Primary completion
Jul 27, 2023
Study completion Jul 27, 2023
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- Denali Therapeutics Inc.
- First posted
- Jun 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). The study will focus on participants with a specific genetic variant in their LRRK2 gene. The main question researchers are trying to answer is if taking BIIB122 slows the worsening of PD more than placebo in the early stages of PD. To help answer this question, researchers will use a questionnaire called the Movement Disorder Society-Unified Parkinson's Disease Rating Scale, also known as the MDS-UPDRS. * The MDS-UPDRS measures impairment and disability in people living with PD. It was created in the 1980s and is one of the most used rating scales for PD symptoms. * The MDS-UPDRS has 4 parts, and a higher score means more severe PD symptoms. * Part I assesses non-motor experiences of daily living, including but not limited to memory loss, problems sleeping, pain, depression, and anxiety. * Part II measures motor experiences of daily living. * Part III is the results of a motor symptoms exam by a medical professional. * Part IV records PD complications caused by motor symptoms. Researchers will also learn more about the safety of BIIB122. A description of how the study will be done is given below. * Participants will take BIIB122 or a placebo as tablets by mouth. A placebo looks like the study drug but contains no real medicine. * Participants will be in the study for 103 weeks to 187 weeks. This includes the screening and follow-up periods. * Participants will take BIIB122 or placebo 1 time a day for 96 to 180 weeks. * Participants can continue to take certain medications for PD. Participants must be on the same dose of medication for at least 90 days before the study begins. * Participants will visit the clinic less often as the study continues, ranging every 4 weeks to every 24 weeks.
Conditions
- Parkinson Disease
Interventions
BIIB122Drug
Administered as specified in the treatment arm.
BIIB122-Matching PlaceboDrug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Confirmed Worsening in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and IIITime frame: From Week 96 to Week 180
Locations
27 sites in 6 countries. Site status is shown where the registry gives one.
University of California San Francisco (UCSF)
San Francisco, California
University of Colorado
Aurora, Colorado
Rocky Mountain Movement Disorders Center, PC
Englewood, Colorado
Parkinson's Disease and Movement Disorders Center
Boca Raton, Florida
USF Health Byrd Institute
Tampa, Florida
University of Kansas Medical Center Research Institute, Inc.
Kansas City, Kansas
Massachusetts General Hospital
Boston, Massachusetts
Mount Sinai Beth Israel
New York, New York
Weill Medical College of Cornell University
New York, New York
Pennsylvania Hospital
Philadelphia, Pennsylvania
Evergreen Hospital Medical Center
Kirkland, Washington
Inland Northwest Research
Spokane, Washington
Groupe Hospitalier Pitie-Salpetriere
Paris, France
Hôpital de la Timone
Marseille, Bouches-du-Rhône, France
Hopital Purpan
Toulouse, Haute Garonne, France
CHU Rennes - Hopital Pontchaillou
Rennes, Ille Et Vilaine, France
Centre Hospitalier Universitaire de Lyon-Hospices Civils de Lyon-Hopital Pierre Wertheimer
Bron, Rhone, France
Universitaetsklinikum Carl Gustav Carus TU Dresden
Dresden, Germany
Universitaetsklinikum Tuebingen
Tübingen, Baden-Wurttemberg, Germany
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital General de Catalunya
Sant Cugat del Vallès, Barcelona, Spain
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain
Hospital Universitario Donostia
Donostia / San Sebastian, Guipuzcoa, Spain
Ninewells Hospital
Dundee, Tayside Region, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.